Skip to content
OpenCapital
Get started

Disc Medicine IRON Internal Research And Development — Research And Development Expense

Other product segments

Bitopertin
$9.34M+10.7%
DISC Three Four Zero Five
$9.19M+451%
DISC Zero Nine Seven Four
$8.11M+32.5%
Other Research
$2.17M+18.2%

Similar metrics at other companies

Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
BioCryst Pharmaceuticals logo
BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)
$3.97M+30.4%
Dianthus Therapeutics logo
DNTHPersonnel And Related Costs — Research And Development Expense
$8.64M+47.7%
Tango Therapeutics logo
TNGXPersonnel-Related Expenses-RD — Research And Development Expense
$12.93M-6.6%
Scholar Rock logo
SRRKEarly Research — Research And Development Expense
$1.21M-16.8%
Scholar Rock logo
SRRKRD Expense Srk439 — Research And Development Expense
$1.76M-58.9%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0×0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's internal research and development — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's internal research and development — research and development expense?
Disc Medicine (IRON) reported internal research and development — research and development expense of $11.31M in Q1 2026.
How has Disc Medicine's internal research and development — research and development expense changed year-over-year?
Disc Medicine's internal research and development — research and development expense increased by 67.6% year-over-year, from $6.75M to $11.31M.
What is the long-term trend for Disc Medicine's internal research and development — research and development expense?
Over 2 years (2023 to 2025), Disc Medicine's internal research and development — research and development expense has grown at a 51.2% compound annual growth rate (CAGR), from $16.17M to $36.95M.
What does internal research and development — research and development expense mean?
This metric represents the total operating costs incurred by the company specifically for internal research and development activities related to its hematologic therapeutic pipeline. It captures the investment in clinical and preclinical product candidates, including personnel costs, laboratory expenses, and clinical trial expenditures. Monitoring this expense provides insight into the company's commitment to advancing its drug development portfolio and its long-term innovation strategy.